Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 21: Which of the following is NOT a side effect of progesterone in hormone replacement therapy?

A. Acne
B. Leg cramps (Correct Answer)
C. Irritability
D. Constipation

Explanation: **Explanation:** In Hormone Replacement Therapy (HRT), progesterone is primarily added to estrogen to prevent endometrial hyperplasia and carcinoma in women with an intact uterus. Understanding its side-effect profile is crucial for NEET-PG. **1. Why Leg Cramps is the Correct Answer:** Leg cramps are a classic side effect associated with **Estrogen** therapy, not progesterone. Estrogen can cause fluid retention and changes in electrolyte balance, leading to muscle cramps. In contrast, progesterone has a mild diuretic effect (antimineralocorticoid action), making it an unlikely cause of leg cramps. **2. Analysis of Incorrect Options (Progesterone Side Effects):** * **Acne:** Progesterone (especially synthetic progestins derived from 19-nortestosterone) has androgenic activity, which stimulates sebaceous glands, leading to acne and oily skin. * **Irritability:** Progesterone and its metabolites (like allopregnanolone) act on GABA receptors in the brain. While they often have a sedative effect, they can cause "PMS-like" symptoms, including irritability, mood swings, and depression in sensitive individuals. * **Constipation:** Progesterone acts as a smooth muscle relaxant. By reducing the motility of the gastrointestinal tract, it increases transit time, leading to constipation. **Clinical Pearls for NEET-PG:** * **The "Gold Standard" for Menopause:** HRT is the most effective treatment for vasomotor symptoms (hot flashes). * **Progesterone Requirement:** If a woman has undergone a hysterectomy, estrogen-only therapy (ERT) is given. Progesterone is *only* added if the uterus is present to protect the endometrium. * **Other Progesterone Side Effects:** Breast tenderness (mastalgia), bloating, and breakthrough bleeding. * **Metabolic Impact:** Progestins can sometimes negate the beneficial effects of estrogen on the lipid profile (by decreasing HDL).

Question 22: What is the average age range for attaining menopause?

A. 40 - 50 years
B. 45 - 55 years (Correct Answer)
C. 55 - 60 years
D. 58 - 68 years

Explanation: **Explanation:** **1. Understanding the Correct Answer (Option B):** Menopause is defined as the permanent cessation of menstruation due to the loss of ovarian follicular activity, clinically diagnosed after 12 consecutive months of amenorrhea. Globally, the average age of menopause is approximately **51 years**, with a normal range typically spanning from **45 to 55 years**. In the Indian context, studies often suggest a slightly earlier onset (mean age ~47–48 years), but the standard medical textbook range remains 45–55 years. **2. Analysis of Incorrect Options:** * **Option A (40–50 years):** While some women enter menopause in their early 40s, the bulk of the population transitions later. Cessation of menses before age 40 is pathologically classified as **Premature Ovarian Insufficiency (POI)**. * **Option C & D (55–68 years):** These ranges are significantly higher than the biological norm. Menopause occurring after age 55 is termed **Late Menopause**, which is a risk factor for endometrial and breast cancer due to prolonged estrogen exposure. **3. High-Yield NEET-PG Clinical Pearls:** * **Premature Menopause:** Occurs before age 40. * **Early Menopause:** Occurs between ages 40 and 45. * **First Sign of Impending Menopause:** Shortening of the follicular phase (leading to a shorter menstrual cycle). * **Best Biochemical Marker:** Elevated **FSH levels >40 IU/L** (due to loss of negative feedback from inhibin and estrogen). * **Smoking:** The only significant lifestyle factor proven to lower the age of menopause by approximately 1.5 to 2 years. * **Genetics:** The age of menopause is primarily genetically determined; it is not affected by the age of menarche, number of pregnancies, or use of oral contraceptives.

Question 23: Which clinical sign indicates the onset of menopause?

A. The onset of menses near age 50
B. An increase in plasma FSH levels (Correct Answer)
C. An excessive presence of corpora lutea
D. An increased number of cornified cells in the vagina

Explanation: **Explanation:** The transition to menopause is characterized by the depletion of ovarian follicles. As the number of viable follicles decreases, there is a significant decline in the production of **Inhibin B** and **Estradiol**. Due to the loss of negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis, the anterior pituitary increases the secretion of **Follicle-Stimulating Hormone (FSH)**. * **Why Option B is correct:** An elevated serum FSH level (typically **>40 IU/L**) is the most reliable biochemical marker for menopause. It is the earliest and most significant hormonal change observed during the climacteric period. **Analysis of Incorrect Options:** * **Option A:** Menopause is defined as the *permanent cessation* of menses (amenorrhea for 12 consecutive months), not the onset of menses. * **Option C:** Corpora lutea are formed after ovulation. In menopause, anovulation is the rule due to follicular depletion; therefore, corpora lutea are absent, not excessive. * **Option D:** Cornified (superficial) cells in a vaginal smear are a sign of estrogenic activity. In menopause, the lack of estrogen leads to a predominance of **basal and parabasal cells**, resulting in an atrophic smear. **NEET-PG High-Yield Pearls:** * **Earliest hormonal change:** Decrease in Inhibin B. * **Most sensitive diagnostic marker:** Elevated FSH (FSH > LH). * **Estrogen status:** Estradiol (E2) levels fall (<20 pg/ml), and **Estrone (E1)** becomes the predominant estrogen (derived from peripheral conversion of androstenedione in adipose tissue). * **Average age:** 50–51 years in the West; approximately 47–48 years in India.

Question 24: Why is progesterone added to estrogen hormone replacement therapy?

A. Postmenopausal lady with a uterus (Correct Answer)
B. TFS/AIS syndrome
C. Postmenopausal patient after hysterectomy
D. All of the above

Explanation: In Hormone Replacement Therapy (HRT), the primary goal of adding progesterone is **endometrial protection**. [3] ### Why Option A is Correct In a postmenopausal woman with an intact uterus, administering **unopposed estrogen** (estrogen alone) leads to continuous proliferation of the endometrial lining. [1][4] Without the stabilizing effect of progesterone, this can result in endometrial hyperplasia and significantly increases the risk of **endometrial carcinoma**. [1][4] Adding a progestogen induces a "secretory" change in the endometrium and promotes periodic shedding, thereby neutralizing the oncogenic risk of estrogen. [3] ### Why Other Options are Incorrect * **Option B (TFS/AIS):** In Testicular Feminization Syndrome (Androgen Insensitivity Syndrome), the individual has a 46,XY karyotype and lacks a uterus. Since there is no endometrium to protect, progesterone is unnecessary; only estrogen is required for feminization and bone health. * **Option C (After Hysterectomy):** If the uterus has been surgically removed, there is no risk of endometrial cancer. These patients are prescribed **Estrogen-only HRT (ERT)**. Adding progesterone is avoided as it may unnecessarily increase the risk of breast cancer and cardiovascular side effects. [2] ### High-Yield NEET-PG Pearls * **Gold Standard:** Estrogen is the most effective treatment for vasomotor symptoms (hot flashes). [2] * **Exception:** If a patient has a history of **endometriosis** even after a hysterectomy, combined HRT may be considered to prevent the malignant transformation of residual ectopic endometrial tissue. * **Route:** Transdermal estrogen is preferred in patients with hypertension, gallstones, or a high risk of VTE, as it bypasses the first-pass hepatic metabolism. * **WHI Study Fact:** Combined HRT (E+P) is associated with a slightly increased risk of breast cancer compared to ERT alone.

Question 25: A 50-year-old woman, who has attained menopause, presents with one episode of post-vaginal bleeding. Which of the following investigations should be performed?

A. Assess for history of hormone replacement therapy, Pap smear, and endometrial biopsy (Correct Answer)
B. Assess for history of hormone replacement therapy and endometrial biopsy
C. Hysterectomy and Pap smear
D. Hysterectomy, dysfunctional uterine bleeding workup, and endometrial biopsy

Explanation: **Explanation:** Postmenopausal bleeding (PMB) is a "red flag" symptom that must be considered **endometrial carcinoma** until proven otherwise. The primary goal of investigation is to rule out malignancy of the genital tract. **Why Option A is Correct:** The management of PMB requires a systematic approach: 1. **History of HRT:** Exogenous estrogens (without progesterone) are a major risk factor for endometrial hyperplasia and cancer. 2. **Pap Smear:** While PMB is often uterine in origin, it can also be caused by cervical cancer. A Pap smear is essential to screen for cervical pathology. 3. **Endometrial Biopsy (EMB):** This is the gold standard for diagnosing endometrial cancer. In clinical practice, a Transvaginal Ultrasound (TVS) is often done first (looking for an endometrial thickness >4 mm), but a definitive tissue diagnosis via EMB or D&C is mandatory if the thickness is increased or bleeding persists. **Analysis of Incorrect Options:** * **Option B:** Incomplete. It misses the evaluation of the cervix (Pap smear), which is a potential site of malignancy presenting as bleeding. * **Option C:** Hysterectomy is a definitive *treatment*, not an initial *investigation*. Surgery should never be performed without a tissue diagnosis. * **Option D:** "Dysfunctional Uterine Bleeding" (DUB) is a diagnosis of exclusion in reproductive-aged women. In a 50-year-old menopausal woman, the focus must be on ruling out organic malignancy, not hormonal dysfunction. **Clinical Pearls for NEET-PG:** * **Most common cause of PMB:** Senile/Atrophic vaginitis (due to estrogen deficiency). * **Most serious cause to rule out:** Endometrial Carcinoma (found in ~10% of PMB cases). * **Cut-off for TVS:** An endometrial thickness (ET) of **≤4 mm** has a high negative predictive value for cancer. If ET >4 mm, biopsy is mandatory. * **Risk Factors:** Obesity, Nulliparity, Early menarche/Late menopause, and Tamoxifen use.

Question 26: Menopause is defined as cessation of menstruation for how long?

A. 3 consecutive months
B. 6 consecutive months
C. 12 consecutive months (Correct Answer)
D. 15 consecutive months

Explanation: **Explanation:** **1. Why 12 consecutive months is correct:** Menopause is a retrospective clinical diagnosis. It is defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity. Clinically, a woman is considered to have reached menopause only after experiencing **12 consecutive months of amenorrhea** in the absence of any other pathological or physiological cause (such as pregnancy or lactation). This duration is chosen because it marks the point where the likelihood of spontaneous ovulation or resumption of menses is statistically negligible. **2. Why other options are incorrect:** * **3 and 6 months (Options A & B):** These durations are characteristic of the **perimenopausal transition** or "secondary amenorrhea" (if occurring earlier in life). During perimenopause, cycles become irregular and "skipped periods" are common, but the ovaries may still produce enough estrogen to trigger occasional bleeding. Diagnosing menopause at 6 months would lead to many false positives. * **15 months (Option D):** While a woman at 15 months is certainly menopausal, this exceeds the standard diagnostic criteria. The 12-month mark is the globally accepted threshold (WHO/STRAW criteria). **3. NEET-PG High-Yield Pearls:** * **Average Age:** 51 years in the West; approximately **47.5–48 years** in India. * **Hormonal Profile:** The hallmark is a **rise in FSH (>40 IU/L)** and a **decrease in Estradiol (<20 pg/ml)**. FSH is the most sensitive diagnostic marker. * **Premature Ovarian Insufficiency (POI):** Menopause occurring before the age of **40**. * **Early Menopause:** Occurring between ages 40 and 45. * **Post-menopausal Bleeding:** Any vaginal bleeding occurring after the 12-month amenorrhea mark is "Post-menopausal bleeding" and must be investigated to rule out endometrial carcinoma.

Question 27: Hormone replacement therapy is not indicated for which of the following conditions?

A. Urogenital atrophy
B. Vasomotor symptoms
C. Prevention of osteoporosis
D. Prevention of coronary artery disease (Correct Answer)

Explanation: **Explanation:** The primary goal of Hormone Replacement Therapy (HRT) is the management of menopausal symptoms and the prevention of bone loss. **Why Option D is correct:** Historically, it was believed that HRT provided cardioprotection. However, large-scale clinical trials, specifically the **Women’s Health Initiative (WHI)**, demonstrated that HRT (especially combined estrogen-progestogen) does not prevent coronary artery disease (CAD). In fact, initiating HRT in older postmenopausal women may **increase** the risk of thromboembolic events and cardiovascular morbidity. Therefore, HRT is strictly **not indicated** for the primary or secondary prevention of CAD. **Analysis of Incorrect Options:** * **A. Urogenital atrophy:** Estrogen deficiency leads to vaginal dryness, dyspareunia, and urinary urgency. Low-dose topical or systemic HRT is the gold standard treatment for these symptoms. * **B. Vasomotor symptoms:** Hot flashes and night sweats are the most common indications for HRT. It remains the most effective treatment for moderate-to-severe vasomotor instability. * **C. Prevention of osteoporosis:** Estrogen inhibits osteoclast activity. HRT is FDA-approved for the prevention of postmenopausal osteoporosis, particularly in women at high risk of fractures who cannot tolerate other therapies. **High-Yield Clinical Pearls for NEET-PG:** * **Window of Opportunity Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. * **Contraindications:** Undiagnosed vaginal bleeding, active liver disease, history of VTE, and estrogen-dependent tumors (Breast/Endometrial CA). * **Addition of Progestogen:** In women with an intact uterus, progestogen must be added to estrogen to prevent **endometrial hyperplasia/carcinoma**. For women post-hysterectomy, Estrogen-only therapy (ERT) is used.

Question 28: Menopause is diagnosed by which of the following biochemical parameters?

A. Estradiol >20 pg/ml
B. Progesterone <40 ng/dl
C. FSH>40 IU/L (Correct Answer)
D. LH<20 IU/L

Explanation: ### Explanation **Correct Answer: C. FSH > 40 IU/L** **Why it is correct:** Menopause is defined as the permanent cessation of menstruation due to the loss of ovarian follicular activity. As the ovarian reserve depletes, there is a significant drop in **Inhibin B** and **Estradiol**. The loss of negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis leads to a compensatory rise in Gonadotropins. **Follicle Stimulating Hormone (FSH)** is the most sensitive biochemical marker for menopause. A serum FSH level **>40 IU/L** (on two occasions, 1 month apart) is considered diagnostic, though levels >30 IU/L in the presence of amenorrhea are clinically highly suggestive. **Why the other options are incorrect:** * **A. Estradiol >20 pg/ml:** In menopause, estradiol levels typically **decrease** significantly, usually falling **below 20 pg/ml**. High levels would indicate active follicular development. * **B. Progesterone <40 ng/dl:** While progesterone is low in menopause due to lack of ovulation (no corpus luteum), it is not a specific diagnostic marker for menopause as it also fluctuates during the normal menstrual cycle. * **D. LH <20 IU/L:** Luteinizing Hormone (LH) actually **increases** during menopause (typically >20–30 IU/L) due to the lack of feedback inhibition, but FSH rises earlier and more significantly than LH, making FSH the preferred marker. **High-Yield Clinical Pearls for NEET-PG:** 1. **Earliest biochemical change** of perimenopause: Decrease in **Inhibin B**. 2. **Most sensitive marker** for ovarian reserve: **AMH (Anti-Müllerian Hormone)**; it decreases before FSH rises. 3. **FSH/LH Ratio:** In menopause, the ratio is **>1** (FSH rises more than LH). 4. **Clinical Diagnosis:** Menopause is primarily a retrospective clinical diagnosis (12 months of amenorrhea); biochemical tests are usually reserved for premature ovarian insufficiency or post-hysterectomy cases.

Question 29: Which of the following conditions is indicated for hormone therapy in menopausal women?

A. Hot flashes (Correct Answer)
B. Breast cancer
C. Endometriosis
D. Uterine bleeding

Explanation: **Explanation:** **1. Why "Hot flashes" is correct:** Hormone Replacement Therapy (HRT) is the most effective treatment for **vasomotor symptoms (VMS)**, such as hot flashes and night sweats. These symptoms occur due to the narrowing of the thermoregulatory window in the hypothalamus caused by declining estrogen levels. Estrogen therapy (with progestogen in women with an intact uterus) stabilizes this mechanism, providing significant relief. According to current guidelines, the primary indication for HRT is the management of moderate-to-severe menopausal symptoms in women under 60 years or within 10 years of menopause onset. **2. Why the other options are incorrect:** * **Breast Cancer:** This is an **absolute contraindication** for HRT. Estrogen can stimulate the growth of estrogen-receptor-positive breast cancer cells and increase the risk of recurrence. * **Endometriosis:** While not always a strict contraindication, HRT (especially estrogen-only) can cause the reactivation of residual endometriotic implants and potentially lead to malignant transformation. It is a condition requiring extreme caution, not an indication. * **Uterine Bleeding:** Undiagnosed abnormal genital bleeding is an **absolute contraindication**. HRT can mask or exacerbate underlying pathologies like endometrial hyperplasia or carcinoma, which must be ruled out before starting therapy. **3. High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Indication:** Vasomotor symptoms (Hot flashes). * **Window of Opportunity:** HRT is safest when started before age 60 or within 10 years of menopause. * **Uterus Rule:** If the uterus is present, always give **Estrogen + Progesterone** to prevent endometrial hyperplasia/cancer. If the patient has had a hysterectomy, give **Estrogen alone**. * **Other Indications:** Prevention of postmenopausal osteoporosis and treatment of genitourinary syndrome of menopause (GSM).

Question 30: Which of the following cells predominate on vaginal cytology in menopausal women?

A. Intermediate cells
B. Superficial cells
C. Parabasal cells (Correct Answer)
D. Superficial cells and intermediate cells

Explanation: The maturation of the vaginal epithelium is directly dependent on **estrogen levels**. This question tests your understanding of the **Maturation Index (MI)**, which represents the ratio of parabasal to intermediate to superficial cells. ### **Why Parabasal Cells are Correct** In menopausal women, there is a significant decline in circulating estrogen. Estrogen is responsible for the proliferation and maturation of the vaginal squamous epithelium. Without it, the epithelium fails to mature beyond the most basic layers. * **Parabasal cells** are small, round, immature cells with large nuclei. * In a low-estrogen state (menopause, prepuberty, or postpartum), the vaginal smear shows an "atrophic" pattern dominated by these **parabasal cells**. ### **Why Other Options are Incorrect** * **Superficial Cells (B):** These are large, flat cells with pyknotic nuclei. They predominate under high estrogen influence (e.g., during **ovulation**). * **Intermediate Cells (A):** These cells predominate under the influence of **progesterone** (e.g., during the luteal phase of the cycle or during **pregnancy**). * **Superficial and Intermediate Cells (D):** This combination is typical of a reproductive-age woman with a functioning hypothalamic-pituitary-ovarian axis, not a menopausal woman. ### **High-Yield Clinical Pearls for NEET-PG** 1. **Maturation Index (MI):** Expressed as (Parabasal % : Intermediate % : Superficial %). * **Menopause:** Shift to the left (e.g., 100:0:0). * **Ovulation:** Shift to the right (e.g., 0:40:60). * **Pregnancy:** Shift to the middle (e.g., 0:95:5). 2. **Vaginal pH:** In menopause, the lack of estrogen leads to decreased glycogen in cells. Less glycogen means fewer *Lactobacilli* and less lactic acid, causing the vaginal pH to rise (**pH > 5.0**), predisposing to atrophic vaginitis. 3. **Fern Test:** Estrogen causes "ferning" of cervical mucus; progesterone (and thus menopause/pregnancy) causes a "beaded" or "cellular" pattern.

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?